{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The MTD will be considered the dose below where \\<= 3 patients experience a DLT and the dose that two cycles can be given without meeting toxicity criteria.","groups":[{"description":"Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d\n\nMelphalan: IV over 30 min, Day 1 q28d\n\nVelcade®: IV bolus, Day 1, 4, 8, 11 q28d\n\nDose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2","id":"OG000","title":"Doxil® + Melphalan + Velcade (DMV)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Maximum Tolerated Dose (MTD) (Phase 1)","type":"PRIMARY"}